FDA PMTA Decisions for Nicotine Pouches: Complete 2021–2026 Timeline

TL;DR

The FDA has issued marketing authorization decisions for only two nicotine pouch brands as of June 2026: ZYN (20 SKUs authorized January 16, 2025) and on! PLUS (6 SKUs authorized December 19, 2025). All other major brands including VELO, Rogue, Lucy, and FRE remain under PMTA review without authorization. This comprehensive timeline tracks every FDA decision from the September 9, 2020 PMTA deadline through June 2026.

Understanding the PMTA Requirement

The Family Smoking Prevention and Tobacco Control Act of 2009 granted the FDA authority to regulate tobacco products through the Center for Tobacco Products. Following the 2016 Deeming Rule extension, all nicotine pouch manufacturers had to submit Premarket Tobacco Product Applications by September 9, 2020 to continue marketing their products.

The PMTA process requires manufacturers to demonstrate their product is "appropriate for the protection of public health" based on factors including health risks to users, non-users, and population-level impacts. Products with timely PMTAs can remain on the market during FDA review under enforcement discretion.

Complete FDA Decision Timeline: 2020–2026

Initial PMTA Submission Deadline

Marketing Authorization Decisions

Products Still Under Review (as of June 26, 2026)

What FDA Authorization Means for Consumers

For adults 21 and older who use nicotine pouches, FDA marketing authorization provides regulatory clarity about which products have undergone comprehensive federal review. The authorization process evaluates:

• Product ingredients and design: Complete formulation disclosure and manufacturing standards
• Health impact data: Toxicological testing and comparative risk assessments
• Marketing plans: How products will be advertised and distributed
• Youth access prevention: Measures to prevent underage access and appeal

The FDA's tobacco product review process does not mean products are "safe" or "FDA approved" for therapeutic use. Authorization indicates the FDA determined marketing the product is appropriate for public health protection based on submitted evidence.

Industry Impact and Market Dynamics

ZYN's January 2025 authorization marked a watershed moment for the nicotine pouch category. As the first and only tobacco-free nicotine pouch brand to receive FDA marketing authorization for over a year, Swedish Match (acquired by Philip Morris International in 2022) gained significant competitive advantage.

The December 2025 authorization of six on! PLUS SKUs from Helix Innovations (an Altria subsidiary) expanded the authorized product landscape, though notably excluded the 3mg strength variant of on! PLUS Mint. This selective authorization pattern demonstrates the FDA's product-specific evaluation approach.

Major brands including VELO, Rogue, Lucy, and FRE continue operating under enforcement discretion while their PMTAs remain under FDA review. The agency has not publicly disclosed review timelines for pending applications.

Regulatory Context: The 2020 PMTA Deadline

The September 9, 2020 deadline stemmed from the FDA's 2016 final rule deeming all tobacco products subject to agency authority. Manufacturers received a four-year compliance period to prepare and submit applications.

According to FDA press announcements, the agency received over 6.5 million PMTA submissions across all tobacco product categories by the September 2020 deadline. The vast majority were for flavored e-cigarette products, though hundreds of applications covered nicotine pouches.

What's Next: Future Authorization Expectations

The FDA has not provided public timelines for pending nicotine pouch PMTA reviews. Several factors influence review duration:

• Application completeness: Whether submissions included all required data and studies
• Scientific complexity: Novel ingredients or designs requiring additional evaluation
• Agency resources: FDA staffing and prioritization across tobacco categories
• Manufacturer responses: Time needed to address FDA questions or deficiency letters

Products without submitted PMTAs or those receiving Marketing Denial Orders cannot be legally marketed. The FDA has enforcement authority to remove unauthorized products from the market.

Consumers and retailers should verify product authorization status through official FDA tobacco product listings rather than relying on manufacturer claims. As of June 26, 2026, only ZYN and on! PLUS (specific SKUs) have received FDA marketing authorization.

Key Takeaways for Adults 21 and Older

1. Limited authorizations: Only 26 total nicotine pouch SKUs (20 ZYN + 6 on! PLUS) have FDA marketing authorization as of June 2026
2. Pending reviews ongoing: Major brands including VELO, Rogue, Lucy, and FRE remain under PMTA review without authorization
3. Enforcement discretion: Products with timely PMTAs can remain on market during review
4. Product-specific decisions: FDA evaluates each SKU individually, not entire brand lines
5. No approval timeline: The agency has not disclosed when pending applications will be decided

The nicotine pouch regulatory landscape continues evolving as the FDA works through its PMTA backlog. Adults 21 and older seeking current product authorization status should consult official FDA resources for the most accurate information.